New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:50 EDTMDCOThe Medicines Co. announces EMA accepts MAA for oritavancin
The Medicines Company announced that the European Medicines Agency has accepted for review a marketing authorization application for the investigational intravenous antibiotic, oritavancin, for the treatment of complicated skin and skin tissue infections caused by susceptible gram-positive bacteria, including by methicillin-resistant Staphylococcus aureus, administered as a single dose. The oritavancin MAA is based on data from two Phase 3 clinical trials, SOLO I and SOLO II. These Phase 3 trials evaluated the efficacy and safety of a single 1200 mg dose of oritavancin compared to 7 to 10 days of twice-daily vancomycin in adults with cSSTI, including infections caused by MRSA. The combined SOLO studies were conducted in 1,959 patients with 405 of the patients suffering from a cSSTI with a documented MRSA infection. The acceptance of the MAA marks the beginning of the review process in the European Union for oritavancin. Oritavancin is also under review by the US Food and Drug Administration in the U.S.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 1, 2015
12:36 EDTMDCOThe Medicines Co. announces Angiomax clinical trial data
Subscribe for More Information
10:16 EDTMDCOOptions with decreasing implied volatility
Options with decreasing implied volatility: UVXY MDCO CAM BRCM ANF SRPT TZA WDAY MEMP ZOES
07:07 EDTMDCOMedicine Co.'s cangrelor's CHAMPION PHOENIX trial shows 'effective' results
Researchers at ESC Congress 2015 presented data from secondary analyses of the CHAMPION PHOENIX trial comparing cangrelor, The Medicines Company's fast-acting, rapid offset, intravenous antiplatelet agent, to oral clopidogrel in 11,145 patients undergoing percutaneous coronary intervention. Data demonstrate consistent reductions by more than 20% in the risk of primary endpoint ischemic events, which included a composite of death, myocardial infarction, stent thrombosis and repeat revascularization with cangrelor in patients treated by either the femoral or radial approach. The full report of this subgroup analysis will be published in the European Heart Journal. Cangrelor was associated with a 21% reduction in the primary outcome of death, myocardial infarction, repeat revascularization and stent thrombosis in patients treated by the femoral approach and with a 24% reduction in patients treated by the radial approach compared with clopidogrel. Importantly, rates of GUSTO severe or moderate bleeding were low overall, without significant differences between cangrelor and clopidogrel. New European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation have included cangrelor as an option in P2Y12 inhibitor-naive patients undergoing PCI. Additionally, the Guidelines strengthen the recommendation for the use of the radial approach for coronary angiography and PCI.
August 31, 2015
16:23 EDTMDCOOn The Fly: Top stock stories for Monday
Subscribe for More Information
12:20 EDTMDCOOn The Fly: Top stock stories at midday
Stocks on Wall Street were lower at midday, putting the averages on track to close out a down month with a down day. The weakness is being attributed to comments from several Fed officials on the likelihood of interest rates rising sometime this year. Also impacting the negative tone may be the media reports regarding China pulling back on its recent asset purchases to shore up its stock market. ECONOMIC EVENTS: In the U.S., the Chicago PMI dipped to 54.4 in August from 54.7 in July, versus expectations for it to have edged up to 54.5. The Dallas Fed manufacturing survey general activity index fell to -15.8, versus expectations for a reading of -4.0. In Asia, Chinese stocks fell once again, with the Shanghai composite index closing down 0.82% to finish the month of August with a 12% decline. Japan's Nikkei index finished the month with an even worse daily decline, falling about 1.3%, giving the Nikkei an 8% drop during August. In Europe, a flash estimate from Eurostat showed inflation in the euro area remained unchanged at 0.2% in August. COMPANY NEWS: Shares of Phillips 66 (PSX) advanced 3% after Warren Buffett's Berkshire Hathaway (BRK.A) disclosed late Friday a $4.5B stake in the oil and gas refining and marketing company. Berkshire owns of the oil refiner. Berkshire increased its stake in Phillips 66 to nearly 58M shares between August 26 and August 28, according to filings with the SEC... Intel (INTC) and Goldman Sachs (GS) were the top gainers on the Dow and among the only names in the green among the members of the bluechip index, as both stocks benefited from analyst upgrades. Research firm Northland Capital upgraded Intel to Outperform, saying that the PC market has bottomed and that the chipmaking giant should benefit from its pending acquisition of Altera (ALTR), while Evercore ISI upgraded Goldman Sachs to Buy, saying the recent pickup in volatility has led to higher trading volumes, which should give a boost to the typically slowest summer month of the year. MAJOR MOVERS: Among the notable gainers was Vital Therapies (VTL), which gained 14% after the company announced that additional data from its VTI-208 clinical trial were presented this weekend at an international symposium on dialysis in liver disease. Also higher were shares of The Medicines Company (MDCO), which rose 18% after several analyst said that a Phase I trial of the company's ALN-PCSsc cholesterol treatment yielded better than expected results. Shares of The Medicines Company's partner on the drug, Alnylam Pharmaceuticals (ALNY), slipped 4% following the data announcement. Also lower were shares of ConforMIS (CFMS), which fell 18% after the company initiated a voluntary recall of specific serial numbers of patient-specific instrumentation for its knee replacement product systems and lowered its fiscal year revenue guidance. INDEXES: Near midday, the Dow was down 61.37, or 0.37%, to 16,581.64, the Nasdaq was down 16.59, or 0.34%, to 4,811.74, and the S&P 500 was down 8.73, or 0.44%, to 1,980.14.
10:03 EDTMDCOHigh option volume stocks
High option volume stocks: MDCO IR TROV RLGY PAH XRX ACRX
09:24 EDTMDCOOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTMDCOEuropean Society of Cardiology
Subscribe for More Information
09:01 EDTMDCOThe Medicines Co. price target raised to $53 from $40 at Leerink
Subscribe for More Information
08:10 EDTMDCOThe Medicines Co. price target raised to $45 from $34 at JPMorgan
Subscribe for More Information
07:45 EDTMDCORegeneron should be bought on any pullbacks, says RBC Capital
Subscribe for More Information
07:43 EDTMDCOThe Medicines Co. price target raised to $42 from $32 at Citi
Subscribe for More Information
07:38 EDTMDCOThe Medicines Co. price target raised to $46 from $39 at RBC Capital
Subscribe for More Information
07:31 EDTMDCOThe Medicines Company names Fred Eshelman non-executive chairman
Subscribe for More Information
August 30, 2015
15:50 EDTMDCOAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
12:59 EDTMDCOFly Watch: Medicines Co., Alnylam rise ahead of cholesterol study presentation
Subscribe for More Information
10:13 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADP (ADP) upgraded to Outperform from Market Perform at William Blair... ASML (ASML) upgraded to Buy from Hold at Berenberg... Abercrombie & Fitch (ANF) upgraded on Hollister fundamentals at RBC Capital... Akamai (AKAM) upgraded to Outperform from Market Perform at JMP Securities... Ares Capital (ARCC) upgraded to Outperform from Market Perform at Raymond James... Banco Santander (SAN) upgraded on valuation at Deutsche Bank... CIBC (CM) upgraded to Neutral from Underperform at Credit Suisse... Canon (CAJ) upgraded to Hold from Sell at Deutsche Bank... Citi (C) upgraded to Buy from Neutral at Guggenheim... (CTRP) upgraded to Buy from Hold at Stifel... El Pollo Loco (LOCO) upgraded at Stifel... Genomic Health (GHDX) upgraded to Market Perform from Underperform at Raymond James... Golar LNG (GLNG) upgraded on valuation, upcoming project completion at Stifel... Habit Restaurants (HABT) upgraded to Buy from Hold at Stifel... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Himax (HIMX) upgraded to Outperform from Neutral at Credit Suisse... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Guggenheim... InterContinental (IHG) upgraded to Outperform from Neutral at Credit Suisse... Knight Transportation (KNX) upgraded to Strong Buy on valuation at Raymond James... LogMeln (LOGM) upgraded to Overweight from Sector Weight at Pacific Crest... Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Jaffray... Qunar (QUNR) upgraded on valuation, positive catalysts at Stifel... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ryder (R) upgraded to Strong Buy from Outperform at Raymond James... SVB Financial (SIVB) upgraded to Buy from Neutral at DA Davidson... Seagate (STX) upgraded to Buy from Hold at Cross Research... Sinopec (SNP) upgraded to Neutral from Sell at Citi... Summit Hotel Properties (INN) upgraded to Outperform at Baird... Texas Capital (TCBI) upgraded to Buy from Neutral at DA Davidson... The Medicines Co. (MDCO) upgraded to Buy from Hold at Jefferies... U.S. Bancorp (USB) upgraded to Buy from Neutral at Guggenheim... Weatherford (WFT) upgraded to Overweight from Equal Weight at Stephens.
06:35 EDTMDCOThe Medicines Co. upgraded to Buy from Hold at Jefferies
Jefferies upgraded The Medicines Co. to Buy and increased its price target to $43 from $29. The firm said company has multiple data readouts for pipeline assets over the next 12-18 months starting with PI data from ALN-PCSsc in patients with elevated LDL on Sunday morning. Jefferies also highlighted the ongoing TANGO 1 trial comparing Carbavance to piperacillin-tazobactam in 850 patients with complicated urinary tract infection with data expected in mid-2016 that should also support its thesis.
August 24, 2015
11:43 EDTMDCOThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use